RxDoctor Payments Data

Quentin Allen, MD

Ophthalmology · Stuart, FLNPI 1164483301

Payments from drug & device makers

$202,729in general payments, 2019–2025

Across 548 payments — averaging $369.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$105K
  • Alcon Research LLC$28K
  • Kala Pharmaceuticals, Inc.$19K
  • Bausch & Lomb Americas Inc.$12K
  • Sun Pharmaceutical Industries Inc.$11K
  • Rxsight Inc$7K
  • plus $21K from 30 others

What the payments were for

  • Consulting fees$135,74567%
  • Speaking & faculty fees$41,33720%
  • Travel & lodging$5,0703%
  • Food & beverage$20,47210%
  • Gifts$1040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$202,729 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$503,464
Medicare patients
754
Services billed
2,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine150$113,528
ProlensaBromfenac Sodium149$50,162
Prednisolone Acetate705$23,145
XiidraLifitegrast14$13,148
LumiganBimatoprost37$10,657
MoxifloxacinMoxifloxacin Hcl557$10,437
Cyclosporine11$4,485
Alphagan PBrimonidine Tartrate16$2,983
Latanoprost133$1,376
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat47$606
Timolol Maleate54$503
Brimonidine Tartrate61$450
ErythromycinErythromycin Base43$371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$2,713$127,167203 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$225$50,162149 claims
Bausch & Lomb Americas Inc.Xiidra$12,020$13,14814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →